logo
DERM_Products
Revenues were $16.1 million for the third quarter of 2022, compared to revenues of $19.6 million for the third quarter of 2021, representing a decline of $3.5 million. The decline in revenue was primarily attributed to a combination of, the continued generic competition of Targadox, that represented a $4.0 million reduction versus the prior year, and a $0.6 million increase in the net revenue of Accutane, which was 17% favorable versus the third quarter of 2021

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate ...

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quarter and nine months ended September 30, 2022

By Journey Medical Corporation
Published - Nov 10, 2022, 04:05 PM ET
Last Updated - Mar 22, 2024, 01:47 PM EDT

Revenue for the first nine months of 2022 increased 26% to $57.7 million versus the same period in 2021 of $45.6 million

DFD-29 Phase 3 studies are 75% enrolled to date

Top-line data from the Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea anticipated in the first half of 2023

Company to hold conference call on November 10, 2022 at 4:30 p.m. ET

Article Source
Quick Links
Categories
Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024